Nimotop (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels on the smooth‑muscle cells of cerebral arteries. This inhibition reduces calcium entry, causing vasodilation of the cerebral vessels, which lessens vasospasm and improves oxygen delivery to brain tissue, providing both vascular and neuroprotective benefits.

The exact dose of Nimotop is determined by the prescribing physician based on clinical guidelines, patient weight, and the severity of the hemorrhage. Typical regimens involve an initial loading dose followed by a maintenance schedule administered intravenously or intracisternally, but the prescriber sets the final dosing plan.

Safety data for nimodipine during pregnancy and lactation are limited. The drug is generally avoided unless the potential therapeutic benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Nimodipine is a dihydropyridine calcium channel blocker with a higher affinity for cerebral vessels, making it especially effective for preventing vasospasm after subarachnoid hemorrhage. Other agents such as nicardipine or verapamil also cause vasodilation but have broader systemic effects and are less selective for the brain, which can result in more pronounced systemic hypotension.

Nimotop should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided by the supplier to maintain sterility and potency.

Nimotop is supplied as a sterile injectable solution and is administered either by intracisternal injection directly into the cerebrospinal fluid or by intravenous infusion. Administration is performed under strict medical supervision in a hospital or clinical setting, with dosing intervals guided by the treating physician.

The most serious adverse events to monitor include severe hypotension, myocardial infarction, allergic reactions such as anaphylaxis, significant liver enzyme elevations, and rare occurrences of seizures. Prompt medical evaluation is required if any of these symptoms develop during therapy.

Patients with a known hypersensitivity to nimodipine or other dihydropyridine calcium channel blockers, those with severe baseline hypotension, or individuals taking contraindicated interacting medications should avoid Nimotop. Clinical judgment is essential to determine suitability for each patient.